Biblio

33557 resultats trouvés
R
Pages P-B, Serayssol C, Brioude G, Falcoz P-E, Brouchet L, Le Pimpec-Barthes F, Thomas P-A, Bernard A.  2016.  Risk factors for survival and recurrence after lung metastasectomy. JOURNAL OF SURGICAL RESEARCH. 203:293-300.
Bennabi D., Aouizerate B., El-Hage W., Doumy O., Moliere F., Courtet P., Nieto I., Bellivier F., Bubrovsky M., Vaiva G. et al..  2015.  Risk factors for treatment resistance in unipolar depression: A systematic review. JOURNAL OF AFFECTIVE DISORDERS. 171:137-141.
Desplanches T, Morgan AS, Jones P, Diguisto C, Zeitlin J, Martin-Marchand L, Benhammou V, Lecomte B, Roze J-C, Truffert P et al..  2021.  Risk factors for very preterm delivery out of a level III maternity unit: The EPIPAGE-2 cohort study. PAEDIATRIC AND PERINATAL EPIDEMIOLOGY. 35:694-705.
Narducci F, Bogart E, Paget-Bailly S, Saadeh R, Le Deley M-C, Riedl C, Borghesi Y, Vanseymortier M, Delbrouck D, Hudry D et al..  2020.  Risk Factors, Morbidity, and Quality of Life Associated with Same-Day Discharge in Gynecologic Oncology. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY. 18:35.
Ellouze O, Abbad X, Constandache T, Missaoui A, Berthoud V, Daily T, Aho S, Bouchot O, Bouhemad B, Guinot P-G.  2021.  Risk Factors of Bleeding in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation. ANNALS OF THORACIC SURGERY. 111:623-628.
Altieri M, Seree O, Lobbedez T, Segol P, Abergel A, Blaizot X, Boillot O, Boudjema K, Coilly A, Conti F et al..  2021.  Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY. 45:101514.
Sfeir R, Rousseau V, Bonnard A, Gelas T, Aumar M, Panait N, Piolat C, Irtan S, Fouquet V, Lemandat A et al..  2021.  Risk Factors of Early Mortality and Morbidity in Esophageal Atresia with Distal Tracheoesophageal Fistula: A Population-Based Cohort Study. JOURNAL OF PEDIATRICS. 234:99+.
Carcopino X, Mancini J, Gondry J, Chevreau J, Lamblin G, Atallah A, Lavoue V, Caradec C, Baldauf J-J, Bryand A et al..  2018.  Risk Factors of Inadequate Colposcopy After Large Loop Excision of the Transformation Zone: A Prospective Cohort Study. JOURNAL OF LOWER GENITAL TRACT DISEASE. 22:31-37.
Demarquet E, Mancini J, Preaubert L, Gondry J, Chevreau J, Lamblin G, Lebail K, Lavoue V, Pinsard M, Baldauf J-J et al..  2019.  Risk Factors of Post-Large Loop Excision of the Transformation Zone Recurrent High-Grade Cervical Intraepithelial Lesion: A Prospective Cohort Study. JOURNAL OF LOWER GENITAL TRACT DISEASE. 23:18-23.
Gallian P, Lhomme S, Morel P, Gross S, Mantovani C, Hauser L, Tinard X, Pouchol E, Djoudi R, Assal A et al..  2020.  Risk for Hepatitis E Virus Transmission by Solvent/ Detergent Treated Plasma. EMERGING INFECTIOUS DISEASES. 26:2881-2886.
Kretz B, Abello N, Bouchot O, Kazandjian C, Beaumont M, Terriat B, Bernard A, Brenot R, Steinmetz E.  2014.  Risk Index for Predicting Shunt in Carotid Endarterectomy. ANNALS OF VASCULAR SURGERY. 28:1204–1212.
Dautriche A., Grandvuillemin A., Fleck C., Combret S., Briet J., Grappin F., Sgro C..  2016.  Risk mapping in the Burgundy regional pharmacovigilance center. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 30:40.
Dautriche A., Grandvuillemin A., Fleck C., Combret S., Briet J., Grappin F., Sgro C..  2016.  Risk mapping in the Burgundy regional pharmacovigilance center. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 30:40.
Rempenault C., Lukas C., Combe B., Schaeverbeke T., Wendling D., Pham T., Mariette X., Gottenberg J.E, Morel J..  2020.  RISK OF DIVERTICULITIS AND GASTRO-INTESTINAL PERFORATION IN RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB COMPARED TO RITUXIMAB AND ABATACEPT: A PROSPECTIVE PROPENSITY-MATCHED COHORT STUDY. ANNALS OF THE RHEUMATIC DISEASES. 79:17.
Rempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaeverbeke T, Wendling D, Pham T, Gottenberg J-E, Mariette X et al..  2022.  Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. RHEUMATOLOGY. 61:953-962.
Gouverneur A., Avouac J., Prati C., Cracowski J.L, Schaeverbeke T., Pariente A., Truchetet M.E.  2021.  RISK OF MAJOR CARDIOVASCULAR EVENT ACROSS JAK INHIBITOR TREATED PATIENTS: ANALYSIS OF A NATIONAL CLAIM DATABASE. ANNALS OF THE RHEUMATIC DISEASES. 80:331-332.
Gouverneur A, Avouac J, Prati C, Cracowski J-L, Schaeverbeke T, Pariente A, Truchetet M-E.  2021.  Risk of major cardiovascular event in JAK inhibitor treated patients: Analysis of a national claim database. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 30:118-119.
Lafarge A, Joseph A, Pagnoux C, Puechal X, Cohen P, Samson M, Hamidou M, Karras A, Groh M, Quemeneur T et al..  2020.  Risk of malignancy in patients treated for systemic necrotising vasculitis. ANNALS OF THE RHEUMATIC DISEASES. 79:431+.
Beaugerie L, Carrat F, Colombel J-F, Bouvier A-M, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron J-L, Simon T et al..  2014.  Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. GUT. 63:1416-1423.
Lampure A, Castetbon K, Deglaire A, Schlich P, Peneau S, Hercberg S, Mejean C.  2015.  The risk of obesity is associated with fat and sweet liking. ANNALS OF NUTRITION AND METABOLISM. 67:347.
Gagniere C., Bourrier A., Seksik P., Gornet J.-M, Dewit O., Nancey S., Altwegg R., Abitbol V., Laharie D., Reenaers C. et al..  2017.  Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID. JOURNAL OF CROHNS & COLITIS. 11:S31-S32.
Charalabidis A, Dechaume-Moncharmont F-X, Petit S, Bohan DA.  2017.  Risk of predation makes foragers less choosy about their food. PLOS ONE. 12:e0187167.
Terrier B, Humbert S, Preta L-H, Delage L, Razanamahery J, Laurent-Roussel S, Mestiri R, Beaudeau L, Legendre P, Goupil F et al..  2020.  Risk of scleroderma according to the type of immune checkpoint inhibitors. AUTOIMMUNITY REVIEWS. 19:102596.
Neumann F, Jegu J, Mougin C, Pretet J-L, Guizard A-V, Lapotre-Ledoux B, Bara S, Bouvier V, Colonna M, Troussard X et al..  2016.  Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study. PREVENTIVE MEDICINE. 90:52-58.
Chalouni M, Wittkop L, Bani-Sadr F, Lacombe K, Esterle L, Gilbert C, Miailhes P, Zucman D, Valantin MAntoine, Bregigeon-Ronot S et al..  2021.  Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants. HIV MEDICINE. 22:791-804.

Pages